Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Hong Kong ETF (EWH) vs Medpace Holdings Inc (MEDP) Price & Performance

iShares MSCI Hong Kong ETFTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Hong Kong ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.47, while Medpace Holdings Inc trades at $599.87 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.

EWHMEDP
Sector
Broad Market / FactorTechnology
52-Week High
$24.55$620.59
52-Week Low
$20.66$393.42
Market Cap
$16.90B
Enterprise Value
$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Hong Kong ETF

EWH, a US-listed ETF tracking Hong Kong equities, trades at $22.45, down 1.54% in the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF announced a $0.35 dividend payable in June 2026. Recent news highlights the Hang Seng Index's rebound, driven by technology stock recoveries, contrasting with declines in other Asian markets like the Kospi and Nikkei 225.

The outlook for EWH is mixed, with potential upside from Hong Kong's market recovery and tech sector momentum, but risks include regional volatility and competitive pressures. Investors should weigh the ETF's exposure to Asian economic shifts and monitor earnings growth from constituent companies for catalysts.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Hong Kong ETF

EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.

Read more on EWH

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP